MariMed (MRMD) Stock Price, News & Analysis

Company Overview

MariMed Inc. engages in cultivation, production, and dispensing of medicinal and recreational cannabis in the United States and internationally. The company sells flowers and concentrates under the Nature's Heritage brand; and soft and chewy baked goods and a hot chocolate mix under Bubby's Baked brand; and drink mix under Vibations brand. It also offers chewable cannabis-infused mint tablet under the brand Kalm Fusion; and flower, vapes, and edibles under InHouse brand. In addition, the company provides supplement, nutrient-infused fruit chews under Betty's Eddies brand and ice creams under Emack & Bolio's brand. The company licenses its brands. MariMed Inc. was incorporated in 2011 and is based in Norwood, Massachusetts.

Key Stats

• Today's Range: $0.08 to $0.10
• 50-Day Range: $0.08 to $0.11
• 52-Week Range: $0.07 to $0.29
• Volume: 1.81 million shs
• Average Volume: 400,762 shs
• Market Capitalization: $33.04 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Strong Buy

MariMed Stock Analysis - MarketRank™

MariMed scored higher than 22% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for MariMed.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of MariMed is -2.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of MariMed is -2.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

MariMed has a P/B Ratio of 0.45. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.02% of the float of MariMed has been sold short.

Short Interest Ratio / Days to Cover

MariMed has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in MariMed has recently decreased by 10.53%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

MariMed does not currently pay a dividend.

Dividend Growth

MariMed does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.02% of the float of MariMed has been sold short.

Short Interest Ratio / Days to Cover

MariMed has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in MariMed has recently decreased by 10.53%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.3 / 5
• News Sentiment: 0.17

News Sentiment

MariMed has a news sentiment score of 0.17. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.85 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for MariMed this week, compared to 1 article on an average week.

Search Interest

1 people have searched for MRMD on MarketBeat in the last 30 days.

MarketBeat Follows

Only 2 people have added MariMed to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, MariMed insiders have not sold or bought any company stock.

Percentage Held by Insiders

18.99% of the stock of MariMed is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 0.18% of the stock of MariMed is held by institutions.

MRMD Stock Analysis - Frequently Asked Questions

How have MRMD shares performed this year?

MariMed's stock was trading at $0.1158 at the beginning of the year. Since then, MRMD shares have decreased by 26.6% and is now trading at $0.0850.
View the best growth stocks for 2025 here.

How were MariMed's earnings last quarter?

MariMed Inc. (OTCMKTS:MRMD) announced its earnings results on Wednesday, May, 7th. The company reported ($0.01) EPS for the quarter, hitting analysts' consensus estimates of ($0.01). The firm earned $37.96 million during the quarter, compared to analyst estimates of $38.33 million. MariMed had a negative net margin of 10.97% and a negative trailing twelve-month return on equity of 2.75%.
Read the conference call transcript.

How do I buy shares of MariMed?

Shares of MRMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of MariMed own?

Based on aggregate information from My MarketBeat watchlists, some other companies that MariMed investors own include Canopy Growth (CGC), Innovative Industrial Properties (IIPR), NVIDIA (NVDA), Curaleaf (CURLF), Aurora Cannabis (ACB), Meta Platforms (META) and Tilray (TLRY).

Company Calendar

• Last Earnings: 5/07/2025
• Today: 5/13/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Drug Manufacturers - Specialty & Generic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: OTCMKTS:MRMD
• CIK: 1522767
• Web: marimedadvisors.com
• Phone: (617) 795-5140
• Fax: N/A
• Employees: 260
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($0.03)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-16,030,000.00
• Net Margins: -10.97%
• Pretax Margin: -5.28%
• Return on Equity: -2.75%
• Return on Assets: -1.06%

Debt

• Debt-to-Equity Ratio: 1.01
• Current Ratio: 1.55
• Quick Ratio: 0.73

Sales & Book Value

• Annual Sales: $148.60 million
• Price / Sales: 0.22
• Cash Flow: $0.02 per share
• Price / Cash Flow: 5.59
• Book Value: $0.19 per share
• Price / Book: 0.45

Miscellaneous

• Outstanding Shares: 388,710,000
• Free Float: 301,649,000
• Market Cap: $33.04 million
• Optionable: Not Optionable
• Beta: 3.15